Executive Summary
Azoth Analytics has released a research report titled "Global Immune Thrombocytopenia Drug Market (2024 Edition)" which provides a complete analysis of the Global Immune Thrombocytopenia Drug industry in terms of market segmentation By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type (Acute, Chronic), By End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India). The Global Immune Thrombocytopenia Drug market showcased growth at a CAGR of 21.32% during 2019-2022. The market was valued at USD 3661.45 Million in 2022 which is expected to reach USD 12308.37 Million in 2029. Immune Thrombocytopenia Drug Market is being propelled by rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.
According to National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years, The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in research and development, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition.
Also, According to National Organization of Rare Disease, In the United States, the annual incidence of ITP is estimated around 3.3 per 100,000 people.3 In Europe, the annual incidence of ITP among adults is estimated at around 1 to 4 per 100,000 people. The growing prevalence of ITP in the has stimulated research and development efforts in the field of ITP drugs. Pharmaceutical companies in these regions have responded to the growing demand for ITP treatments by developing and marketing drugs to address the needs of patients with this condition across different geographic areas.
Novel drug delivery technologies have enhanced the administration and effectiveness of ITP medications. Long-acting formulations, subcutaneous injections, and oral formulations offer improved convenience, reduced dosing frequency, and enhanced patient adherence compared to traditional intravenous therapies. These advancements in drug delivery technology have improved patient comfort and treatment compliance in ITP management.
Advancements in TPO-RAs have led to the development of new agents with improved efficacy and safety profiles. Second-generation TPO-RAs, such as avatrombopag and lusutrombopag, have demonstrated superior platelet response rates and reduced side effects compared to earlier agents like romiplostim and eltrombopag. These advancements have expanded treatment options for patients with ITP and improved treatment outcomes.
Hospitals and clinics have adopted advanced diagnostic technologies to facilitate accurate and timely diagnosis of ITP. Techniques such as flow cytometry, polymerase chain reaction (PCR), and genetic testing allow for the detection of immune dysregulation, autoantibodies, and underlying genetic predispositions in patients with ITP. Advanced diagnostic technologies enable healthcare providers to differentiate primary ITP from secondary causes of thrombocytopenia, guiding treatment decisions and improving patient outcomes.
Technological advancements drive innovation and progress in the global Immune Thrombocytopenia Drug Market, accelerating drug discovery, development, manufacturing, and clinical practice. These advancements enhance biomarker discovery, high-throughput screening, computational modeling, biopharmaceutical manufacturing, drug delivery systems, and digital health technologies, improving the efficacy, safety, and accessibility of ITP treatments for patients worldwide.
Scope of the Report:
• The report analyses the Immune Thrombocytopenia Drug Market by Value (USD Million).
• The report analyses the Immune Thrombocytopenia Drug Market by Pipeline Scenario.
• The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India).
• The report presents the analysis of Immune Thrombocytopenia Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Immune Thrombocytopenia Drug Market by Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others).
• The report analyses the Immune Thrombocytopenia Drug Market by Type (Acute, Chronic).
• The report analyses the Immune Thrombocytopenia Drug Market by End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By treatment, by type & by end users.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include CSL Behring, Rigel Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceutical, Sanofi, Amgen, Inc., Grifols, Takeda Pharmaceuticals and Intas Pharmaceuticals.
Table of Content
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Amplify development of intravenous drugs for chronic application
2.2 Escalate collaboration initiative with healthcare provider
3. Global Immune Thrombocytopenia Drug Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Immune Thrombocytopenia Drug Market
3.2 Pipeline Scenario
3.3 Frequency of adult secondary Immune Thrombocytopenia
3.4 Global Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
3.5 Degree of Impact of Covid-19 on Immune Thrombocytopenia Drug Market
3.6 Global Immune Thrombocytopenia Drug Market Segmentation: By Treatment
3.6.1 Global Immune Thrombocytopenia Drug Market, By Treatment Overview
3.6.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Treatment Overview
3.6.3 Global Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
3.6.4 Global Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
3.6.5 Global Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
3.6.6 Global Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
3.7 Global Immune Thrombocytopenia Drug Market Segmentation: By Type
3.7.1 Global Immune Thrombocytopenia Drug Market, By Type Overview
3.7.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Type Overview
3.7.3 Global Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
3.7.4 Global Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
3.8 Global Immune Thrombocytopenia Drug Market Segmentation: By End-User
3.8.1 Global Immune Thrombocytopenia Drug Market, By End-User Overview
3.8.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By End-User Overview
3.8.3 Global Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
3.8.5 Global Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
4. Global Immune Thrombocytopenia Drug Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas Immune Thrombocytopenia Drug Market: Historic and Forecast
5.1 Americas Immune Thrombocytopenia Drug Market: Snapshot
5.2 Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas Immune Thrombocytopenia Drug Market: Key Factors
5.4 Americas Immune Thrombocytopenia Drug Market: Segment Analysis
5.5 Americas Immune Thrombocytopenia Drug Market Segmentation: By Treatment
5.5.1 Americas Immune Thrombocytopenia Drug Market, By Treatment Overview
5.5.2 Americas Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
5.5.5 Americas Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas Immune Thrombocytopenia Drug Market Segmentation: By Type
5.6.1 Americas Immune Thrombocytopenia Drug Market, By Type Overview
5.6.2 Americas Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
5.6.3 Americas Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
5.7 Americas Immune Thrombocytopenia Drug Market Segmentation: By End-User
5.7.1 Americas Immune Thrombocytopenia Drug Market, By End-User Overview
5.2.2 Americas Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
5.7.3 Americas Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
5.7.4 Americas Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
5.8 Americas Immune Thrombocytopenia Drug Market Segmentation: By Country
5.8.1 Americas Immune Thrombocytopenia Drug Market, By Country Overview
5.8.2 United States Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.8.2.1 United States Immune Thrombocytopenia Drug Market, By Treatment
5.8.2.2 United States Immune Thrombocytopenia Drug Market, By Type
5.8.2.3 United States Immune Thrombocytopenia Drug Market, By End-User
5.8.3 Canada Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.8.3.1 Canada Immune Thrombocytopenia Drug Market, By Treatment
5.8.3.2 Canada Immune Thrombocytopenia Drug Market, By Type
5.8.3.3 Canada Immune Thrombocytopenia Drug Market, By End-User
5.10.4 Rest of Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.10.4.1 Rest of Americas Immune Thrombocytopenia Drug Market, By Treatment
5.10.4.2 Rest of Americas Immune Thrombocytopenia Drug Market, By Type
5.10.4.3 Rest of Americas Immune Thrombocytopenia Drug Market, By End-User
6. Europe Immune Thrombocytopenia Drug Market: Historic and Forecast
6.1 Europe Immune Thrombocytopenia Drug Market: Snapshot
6.2 Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe Immune Thrombocytopenia Drug Market: Key Factors
6.4 Europe Immune Thrombocytopenia Drug Market: Segment Analysis
6.5 Europe Immune Thrombocytopenia Drug Market Segmentation: By Treatment
6.5.1 Europe Immune Thrombocytopenia Drug Market, By Treatment Overview
6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
6.5.5 Europe Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe Immune Thrombocytopenia Drug Market Segmentation: By Type
6.6.1 Europe Immune Thrombocytopenia Drug Market, By Type Overview
6.6.2 Europe Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe Immune Thrombocytopenia Drug Market Segmentation: By End-User
6.7.1 Europe Immune Thrombocytopenia Drug Market, By End-User Overview
6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
6.8 Europe Immune Thrombocytopenia Drug Market Segmentation: By Country
6.8.1 Europe Immune Thrombocytopenia Drug Market, By Country Overview
6.8.2 United Kingdom Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.2.1 United Kingdom Immune Thrombocytopenia Drug Market, By Treatment
6.8.2.2 United Kingdom Immune Thrombocytopenia Drug Market, By Type
6.8.2.3 United Kingdom Immune Thrombocytopenia Drug Market, By End-User
6.8.3 Germany Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.3.1 Germany Immune Thrombocytopenia Drug Market, By Treatment
6.8.3.2 Germany Immune Thrombocytopenia Drug Market, By Type
6.8.3.3 Germany Immune Thrombocytopenia Drug Market, By End-User
6.8.4 France Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.4.1 France Immune Thrombocytopenia Drug Market, By Treatment
6.8.4.2 France Immune Thrombocytopenia Drug Market, By Type
6.8.4.3 France Immune Thrombocytopenia Drug Market, By End-User
6.8.5 Spain Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.5.1 Spain Immune Thrombocytopenia Drug Market, By Treatment
6.8.5.2 Spain Immune Thrombocytopenia Drug Market, By Type
6.8.5.3 Spain Immune Thrombocytopenia Drug Market, By End-User
6.8.6 Rest of Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.6.1 Rest of Europe Immune Thrombocytopenia Drug Market, By Treatment
6.8.6.2 Rest of Europe Immune Thrombocytopenia Drug Market, By Type
6.8.6.3 Rest of Europe Immune Thrombocytopenia Drug Market, By End-User
7. Asia Pacific Immune Thrombocytopenia Drug Market: Historic and Forecast
7.1 Asia Pacific Immune Thrombocytopenia Drug Market: Snapshot
7.2 Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia Pacific Immune Thrombocytopenia Drug Market: Key Factors
7.4 Asia Pacific Immune Thrombocytopenia Drug Market: Segment Analysis
7.5 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Treatment
7.5.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment Overview
7.5.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
7.5.5 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Type
7.6.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Type Overview
7.6.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By End-User
7.7.1 Asia Pacific Immune Thrombocytopenia Drug Market, By End-User Overview
7.7.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
7.7.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
7.7.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
7.8 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Country
7.8.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Country Overview
7.8.2 China Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.2.1 China Immune Thrombocytopenia Drug Market, By Treatment
7.8.2.2 China Immune Thrombocytopenia Drug Market, By Type
7.8.2.3 China Immune Thrombocytopenia Drug Market, By End-User
7.8.3 Japan Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.3.1 Japan Immune Thrombocytopenia Drug Market, By Treatment
7.8.3.2 Japan Immune Thrombocytopenia Drug Market, By Type
7.8.3.3 Japan Immune Thrombocytopenia Drug Market, By End-User
7.8.4 South Korea Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.4.1 South Korea Immune Thrombocytopenia Drug Market, By Treatment
7.8.4.2 South Korea Immune Thrombocytopenia Drug Market, By Type
7.8.4.3 South Korea Immune Thrombocytopenia Drug Market, By End-User
7.8.5 India Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.5.1 India Immune Thrombocytopenia Drug Market, By Treatment
7.8.5.2 India Immune Thrombocytopenia Drug Market, By Type
7.8.5.3 India Immune Thrombocytopenia Drug Market, By End-User
7.8.6 Rest of Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.6.1 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment
7.8.6.2 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Type
7.8.6.3 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By End-User
8. Middle East and Africa Immune Thrombocytopenia Drug Market: Historic and Forecast
8.1 Middle East and Africa Immune Thrombocytopenia Drug Market: Snapshot
8.2 Middle East and Africa Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle East and Africa Immune Thrombocytopenia Drug Market: Key Factors
8.4 Middle East and Africa Immune Thrombocytopenia Drug Market: Segment Analysis
8.5 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Treatment
8.5.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Treatment Overview
8.5.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle East and Africa Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
8.5.5 Middle East and Africa Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Type
8.6.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Type Overview
8.6.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
8.7 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By End-User
8.7.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By End-User Overview
8.7.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
8.7.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
8.7.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global Immune Thrombocytopenia Drug Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter Analysis
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Share of Leading Companies
11.3 Company Profiling
11.3.1 CSL Behring
11.3.2 Rigel Pharmaceuticals
11.4.3 Novartis
11.3.4 Pfizer
11.3.5 Teva Pharmaceutical
11.3.6 Sanofi
11.3.7 Amgen, Inc.
11.3.8 Grifols
11.3.9 Takeda Pharmaceuticals
11.3.10 Intas Pharmaceuticals
12. About Us and Disclaimer
Request Sample 
Request Discount 
Inquire Before Buy
